Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University College, London
Modality
monoclonal_antibody
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07134842CT.gov A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment. | — | Recruiting | — | — | — |
NCT04817254CT.gov Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | — | Completed | — | — | — |
NCT04396860CT.gov Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | — | Completed | — | — | — |
NCT02311920CT.gov Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gliosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ipilimumab (this asset) | University College, London | P2/3 | BB · 64 |
| Cediranib | Northwestern University | P2 | BBB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BBB |
| Sorafenib | University Hospital, Geneva | P2 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Gefitinib | National Cancer Institute (NCI) | P2 | BB |
| Tandutinib | National Cancer Institute (NCI) | P2 | BB |
| Vorinostat | National Cancer Institute (NCI) | P2 | BB |
| Irinotecan | RTOG Foundation, Inc. | P3 | BB |
+42 more in the Gliosarcoma cohort
Other indications for Ipilimumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P3 | BB · 71 |
| Melanoma | — | P4 | BB · 69 |
| Cutaneous Melanoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CediranibNorthwestern UniversityBBB
- TemsirolimusNational Cancer Institute (NCI)BBB
- SorafenibUniversity Hospital, GenevaBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- GefitinibNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Ipilimumab in Gliosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ipilimumab-gliosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →